PT  - JOURNAL ARTICLE
AU  - Ronald Dahl
AU  - Nicola Gallagher
AU  - Yulia Green
AU  - Hannah Bryant
AU  - Hungta Chen
AU  - Peter D'Andrea
AU  - Vijay Alagappan
AU  - Donald Banerji
TI  - QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD
DP  - 2013 Sep 01
TA  - European Respiratory Journal
PG  - P3385
VI  - 42
IP  - Suppl 57
4099  - http://erj.ersjournals.com/content/42/Suppl_57/P3385.short
4100  - http://erj.ersjournals.com/content/42/Suppl_57/P3385.full
SO  - Eur Respir J2013 Sep 01; 42
AB  - IntroductionRapid onset of bronchodilator action is important in patients with COPD due to the troublesome morning symptoms and their impact on normal activities. The non-adherence to COPD medication regimens can be attenuated by rapid onset of action and decreased frequency to once-daily dosing. Here we present the results of FEV1 data at 5 and 30 min post-dose on Day 1 and Wk 26 for the SHINE and ILLUMINATE studies.MethodsBoth 26wk multicenter, double-blind studies randomized patients (pts) ≥40 yrs with moderate-to-severe COPD to QVA149 (110/50μg), IND (150μg), GLY (50μg), placebo (all via the Breezhaler® device) or tiotropium (TIO, 18μg; via the Handihaler® device) (2:2:2:1:2); and QVA149 (110/50µg) or salmeterol/fluticasone (SFC, 50/500µg; via the Accuhaler® device) (1:1) in the SHINE and ILLUMINATE studies, respectively.ResultsSHINE: 2144 pts randomized; 89.1% completed; mean post-bronchodilator FEV1: 55.2% predicted. ILLUMINATE: 523 pts randomized; 82.6% completed; mean post-bronchodilator FEV1: 60.2% predicted. QVA149 significantly increased the FEV1 at 5 and 30 min on Day 1 and Wk 26 (Table).View this table:Table: Post-dose FEV1ConclusionsOnce-daily QVA149 provided a rapid onset of action and sustained bronchodilation from Day 1 which was significant and maintained for over 26wks compared with IND, GLY, TIO and SFC.